ralimetinib + gemcitabine + carboplatin

Ralimetinib (LY2228820) is a highly selective, oral small molecule inhibitor of p38α and p38β mitogen-activated protein kinases (MAPKs), developed for oncology indications. Its primary anticancer mechanism involves inhibition of the p38 MAPK pathway, which is crucial for tumor cell survival and regulation of pro-inflammatory cytokines, as well as angiogenesis. In addition, ralimetinib can directly inhibit EGFR kinase, although with lower potency compared to p38α. The combination of ralimetinib with gemcitabine (a nucleoside analog cytotoxic chemotherapy) and carboplatin (a platinum-based alkylating agent) has been evaluated in clinical trials for advanced cancers such as platinum-sensitive ovarian cancer, aiming to exploit synergistic mechanisms: cell signaling pathway inhibition (p38 MAPK/EGFR), DNA synthesis inhibition, and DNA crosslinking[1][2][3][4].

Other names

ralimetinib + gemcitabine + carboplatin